What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Clinical evidence suggests that people receiving selpercatinib experience longer periods before their cancer worsens and have improved survival compared to those receiving best supportive care. However, the lack of direct comparison with best supportive care introduces uncertainty regarding the robustness of these findings.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for selpercatinib are within what NICE considers acceptable for Healthcare resources, indicating a defensible economic value.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document indicates improvements in quality of life, it does not provide specific data or validated tools to support these claims, leading to a mixed impact assessment.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of selpercatinib appears favorable, with manageable adverse events reported, although specific adverse event rates are not detailed in the document.
Was the drug compared against what payers expect? — Comparator Selection
Selpercatinib was not directly compared with best supportive care, which raises concerns about the validity of the efficacy claims made in the absence of a head-to-head trial.
Is the population defined the way payers need it? — Patient Population and Subgroups
The patient population for selpercatinib is well-defined, focusing on individuals with advanced RET alteration thyroid cancer, which aligns with the intended use of the therapy.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Selpercatinib can be integrated into existing treatment pathways with minor adjustments, as it is recommended for patients who have already undergone treatment with other targeted therapies.
Are the wider system costs understood? — Resource Use and Cost Implications
The document indicates that the budget impact is manageable and aligns with Healthcare planning, suggesting that resource implications are well-considered.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes data from clinical trials and real-world evidence, although some limitations exist due to the absence of direct comparisons.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the direct comparisons, the context of the treatment’s necessity and its alignment with patient needs mitigates some concerns.
